HK1047892B - HCV vaccine ingredients - Google Patents

HCV vaccine ingredients Download PDF

Info

Publication number
HK1047892B
HK1047892B HK03100096.0A HK03100096A HK1047892B HK 1047892 B HK1047892 B HK 1047892B HK 03100096 A HK03100096 A HK 03100096A HK 1047892 B HK1047892 B HK 1047892B
Authority
HK
Hong Kong
Prior art keywords
hcv
core
immunogenic
antigen
protein
Prior art date
Application number
HK03100096.0A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1047892A1 (en
Inventor
Debbie Drane
John Cox
Michael Houghton
Xavier Paliard
Original Assignee
Csl Limited
Novartis Vaccines And Diagnostics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Limited, Novartis Vaccines And Diagnostics, Inc. filed Critical Csl Limited
Publication of HK1047892A1 publication Critical patent/HK1047892A1/en
Publication of HK1047892B publication Critical patent/HK1047892B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03100096.0A 1999-11-19 2000-11-17 HCV vaccine ingredients HK1047892B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16665299P 1999-11-19 1999-11-19
US166652P 1999-11-19
US22436200P 2000-08-11 2000-08-11
US224362P 2000-08-11
PCT/AU2000/001410 WO2001037869A1 (en) 1999-11-19 2000-11-17 Vaccine compositions

Publications (2)

Publication Number Publication Date
HK1047892A1 HK1047892A1 (en) 2003-03-14
HK1047892B true HK1047892B (en) 2009-01-09

Family

ID=26862451

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100096.0A HK1047892B (en) 1999-11-19 2000-11-17 HCV vaccine ingredients

Country Status (12)

Country Link
US (2) US20040191270A1 (enExample)
EP (1) EP1239876B1 (enExample)
JP (1) JP2003514872A (enExample)
KR (1) KR100875483B1 (enExample)
AT (1) ATE402715T1 (enExample)
AU (1) AU772617B2 (enExample)
CA (1) CA2391843C (enExample)
DE (1) DE60039715D1 (enExample)
ES (1) ES2311478T3 (enExample)
HK (1) HK1047892B (enExample)
NZ (2) NZ518999A (enExample)
WO (1) WO2001037869A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1150710B1 (en) 1999-02-17 2010-04-21 Csl Limited Immunogenic complexes and methods relating thereto
US6562346B1 (en) * 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
JP4370161B2 (ja) * 2001-06-29 2009-11-25 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｈｃｖｅ１ｅ２ワクチン組成物
EP1467755A1 (en) * 2001-12-21 2004-10-20 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
ES2339762T3 (es) * 2002-01-14 2010-05-25 Novartis Vaccines And Diagnostics, Inc. Vacuna contra el vih y procedimiento de uso.
WO2004060396A2 (en) * 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
EP1613647A2 (en) * 2003-04-11 2006-01-11 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Use of hcv proteins
KR20100018029A (ko) * 2004-07-18 2010-02-16 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제
CU23496A1 (es) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
US20070190072A1 (en) * 2004-09-30 2007-08-16 Csl Limited Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus adjuvant
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US9089508B2 (en) * 2007-10-09 2015-07-28 The University Of Melbourne Method of transfection and compositions therefor
US8999353B2 (en) * 2007-10-12 2015-04-07 Csl Limited Method of eliciting an immune response against pandemic influenza virus
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
JP2012523379A (ja) * 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
EP2563389B1 (en) 2010-04-30 2015-07-08 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages
JP2013537892A (ja) 2010-09-22 2013-10-07 ザ ユニバーシティー オブ メルボルン 新規な免疫賦活法
CA2856565A1 (en) * 2010-11-26 2012-05-31 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd. Multimeric hepatitis virus (hcv) envelope 2 (e2) glycoprotein
CU24112B1 (es) * 2012-11-05 2015-08-27 Ct De Ingeniería Genética Y Biotecnología Antígenos vacunales quiméricos contra el virus de la hepatitis c
JP5931113B2 (ja) * 2014-04-08 2016-06-08 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
CN106749672B (zh) * 2016-11-18 2020-06-30 江西农业大学 一种丙型肝炎病毒融合抗原蛋白及其应用
BR112020012360A2 (pt) 2017-12-21 2020-11-24 Ena Therapeutics Pty Ltd compostos otimizados
WO2020257870A1 (en) 2019-06-26 2020-12-30 Ena Therapeutics Pty Ltd Novel molecules

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5897873A (en) * 1984-04-12 1999-04-27 The Liposome Company, Inc. Affinity associated vaccine
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
WO1990001948A1 (en) * 1988-08-25 1990-03-08 The Liposome Company, Inc. Influenza vaccine and novel adjuvants
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5178860A (en) * 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
JP3507486B2 (ja) * 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5273965A (en) * 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
WO1994025602A1 (en) * 1993-05-05 1994-11-10 Common Services Agency Hepatitis-c virus type 4, 5 and 6
ATE249838T1 (de) * 1993-05-12 2003-10-15 Chiron Corp Konserviertes motiv der hepatitis c virus e2/ns1 region
US5451569A (en) * 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
SG71728A1 (en) * 1994-07-29 2000-04-18 Innogenetics Nv Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
AU686891B2 (en) * 1994-10-12 1998-02-12 Iscotec A.B. Saponin preparations and use thereof in iscoms
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
SE9600648D0 (sv) * 1996-02-21 1996-02-21 Bror Morein Receptorbimdande enhet
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69828507T2 (de) * 1997-05-20 2006-01-05 Galenica Pharmaceuticals, Inc. Triterpene-saponin analoga mit adjuvans und immunostimulierender wirkung
DE69838294T2 (de) * 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
DE69838992T2 (de) * 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
ATE335510T1 (de) * 1998-05-22 2006-09-15 Ottawa Health Research Inst Methoden und produkte zur induzierung mukosaler immunität
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DK1104306T3 (da) * 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
FR2783170B1 (fr) * 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
EP1150710B1 (en) * 1999-02-17 2010-04-21 Csl Limited Immunogenic complexes and methods relating thereto
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
US6562346B1 (en) * 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
US6986892B1 (en) * 1999-11-24 2006-01-17 Chiron Corporation Immunogenic Hepatitis C virus non-structural polypeptides
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
EP1478371A4 (en) * 2001-10-12 2007-11-07 Univ Iowa Res Found METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
EP1467755A1 (en) * 2001-12-21 2004-10-20 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
US8153141B2 (en) * 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US7196892B2 (en) * 2002-04-10 2007-03-27 Caelin Gabriel Method and apparatus for isolating RFI, EMI, and noise transients in power supply circuits
MXPA05004588A (es) * 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
MXPA05013973A (es) * 2003-06-17 2006-03-02 Mannkind Corp Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
MXPA05013922A (es) * 2003-06-20 2006-02-24 Coley Pharm Group Inc Antagonistas de receptor tipo toll de molecula pequena.
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
JP2008506683A (ja) * 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ， リミテッド 先天免疫応答を誘導するための方法および組成物
KR20100018029A (ko) * 2004-07-18 2010-02-16 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제
US20070190072A1 (en) * 2004-09-30 2007-08-16 Csl Limited Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus adjuvant
EP1874325A2 (en) * 2005-04-08 2008-01-09 Coley Pharmaceutical Group, Inc. Methods for treating infectious disease exacerbated asthma
AU2007291887B2 (en) * 2006-09-01 2012-09-27 Csl Limited Method of eliciting or inducing an immune response

Also Published As

Publication number Publication date
WO2001037869A9 (en) 2002-07-18
AU1373001A (en) 2001-06-04
NZ520976A (en) 2005-01-28
DE60039715D1 (de) 2008-09-11
KR20020073338A (ko) 2002-09-23
US20040191270A1 (en) 2004-09-30
AU772617B2 (en) 2004-05-06
HK1047892A1 (en) 2003-03-14
KR100875483B1 (ko) 2008-12-22
CA2391843A1 (en) 2001-05-31
JP2003514872A (ja) 2003-04-22
EP1239876A1 (en) 2002-09-18
ES2311478T3 (es) 2009-02-16
WO2001037869A1 (en) 2001-05-31
NZ518999A (en) 2002-12-20
EP1239876B1 (en) 2008-07-30
EP1239876A4 (en) 2003-05-02
US20100047271A1 (en) 2010-02-25
ATE402715T1 (de) 2008-08-15
CA2391843C (en) 2011-10-18

Similar Documents

Publication Publication Date Title
EP1239876B1 (en) Hcv vaccine compositions
NO317546B1 (no) Vaksineblanding, samt anvendelse og fremgangsmate for fremstilling derav
JP6259831B2 (ja) Ｃ型肝炎ウイルスに対するキメラワクチン抗原
US8691234B2 (en) Vaccine formulation potentiated by the combination of DNA and an antigen
EP1785143B1 (en) Vaccine composition against hepatitis c virus
US20250186575A1 (en) Vaccine construct and uses thereof
CN101309931B (zh) 包含截短的hbc核心蛋白和基于皂苷的佐剂的疫苗
Dempster et al. Preclinical safety evaluation of viral vaccines
Simon et al. of adjuvants
Howard New vaccine technologies and the control of viral hepatitis
HK1126228B (en) Vaccines comprising truncated hbc core protein plus saponin-based adjuvants
HK1109069B (en) Vaccine composition against hepatitis c virus

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20141117